Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

The FDA said it plans to accept new forms of real-world evidence in product applications, starting with a subset of medical ...

After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet ...

The FDA has cleared an augmented reality platform for real-time use during brain surgery—which its developer, Medivis, ...

MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. | MapLight Therapeutics is ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to ...

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...